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Abstract: A short inflammatory phase and fast ingrowth of blood vessels and mesenchymal cells
are essential for tissue integration of a biomaterial. Macrophages play a key role in this process.
We investigated invasion of macrophages, blood vessels, and proliferating cells into a highly porous
and volume-stable collagen matrix (VCMX) used for soft tissue augmentation around teeth and
dental implants. The biomaterial was implanted in submucosal pouches in the canine maxilla,
and the tissue response was analyzed at six different time points. Immunohistochemistry was
done for proliferating cells (PCNA), macrophages (MAC387), multinucleated giant cells (CD86),
and blood vessels (TGM2). Blood rapidly filled the VCMX pores. During the first week, MAC387+
cells populated the VCMX pores, blood vessels and PCNA+ cells invaded the VCMX, and CD86+
scattered cells were observed. At 15 days, MAC387+ cells were scanty, blood vessels had completely
invaded the VCMX, the number of proliferating cells peaked, and fibroblasts appeared. At 30 days,
MAC387+ were absent, the numbers of proliferating and CD86+ cells had declined, while blood
vessel and fibroblast numbers were high. At 90 days, residual VCMX was well-integrated in soft
connective tissue. In conclusion, the VCMX elicited a short inflammatory phase followed by rapid
tissue integration.
Keywords: VCMX; Fibro-Gide; collagen matrix; immunohistochemistry; GTR; GBR; volume-stable
collagen matrix
1. Introduction
Biomaterials are widely used in the dental field to overcome the drawbacks of autogenous tissue
transplantation. Lack of an appropriate periodontal or peri-implant soft tissue width and thickness can
compromise esthetics, function, or survival of teeth and dental implants [1,2]. Increase of soft tissue
thickness is a proven strategy to increase keratinized tissues [3,4], quality of mucosa around teeth [1]
and dental implants [5,6], as well as aesthetics [7]. Autogenous connective tissue grafts are used to
correct oral tissue deficiencies [8] and still remain the gold standard for soft tissue augmentation due
to the good maintenance of volume and lack of adverse effects. However, autogenous grafts always
require a donor site, causing morbidity and possible damage of neighboring anatomical structures [9].
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Therefore, biomaterials have been developed as alternatives to increase the amount of soft tissue and
keratinization [10]. They include allografts, xenografts, and synthetic soft tissue substitutes [11–13].
Among the most widely used biomaterials for soft tissue augmentation are collagen matrices of porcine
origin. Although the latter have demonstrated optimal clinical outcomes with uneventful tissue
integration [10], the volume gain tends to be lower when compared to the subepithelial connective
tissue graft [14].
Recently, a new, highly porous, and volume-stable collagen-based matrix (VCMX) was developed
for soft tissue augmentation around teeth and dental implants [15]. Such a biomaterial must be
biocompatible, allow ingrowth of blood vessels and progenitor cells, and withstand mechanical forces
generated as a result of suturing, wound contraction, and mastication, thereby maintaining tissue
volume. In vivo and in vitro studies demonstrated optimal mechanical, biological, and anatomical
properties of the VCMX [16–19]. The collagen matrix consists of 60–96% (w/w) porcine collagen type I
and III and 4–40% (w/w) elastin, has an average pore diameter of 92 µm, and 93% volume porosity
with interconnected pores. Scaffold stiffness was achieved by chemical cross-linking. The scaffold
remained elastic even after mechanical forces were applied for 14 days, as evaluated in a dynamic
bioreactor test system mimicking the mechanical stresses of the human in vivo situation [18]. Clinically,
soft tissue augmentation using VCMX resulted in a volume increase non-inferior to connective tissue
grafts at implant sites in the aesthetic zone [20] and a minimal loss of soft tissue thickness six months
after implantation [21]. The underlying biological process leading to these positive clinical results
is, however, largely unknown. The outcome of wound healing largely depends on the biomaterials’
characteristics (e.g., chemistry, architecture, surface topography). Ideally, a biomaterial should trigger
a short and mild inflammatory period followed by a regenerative phase but no chronic foreign
body reaction leading to biomaterial encapsulation or even rejection. Macrophages are among
the first cells to come in contact with an implanted biomaterial. The biomaterials’ properties can
modulate the phenotype of macrophages, as demonstrated for surface characteristics [22,23], and,
as a consequence, the shift from inflammation (M1 macrophages) to tissue repair and regeneration
(M2 macrophages) may be impaired or delayed. Moreover, the biomaterial may trigger the formation
of multinucleated giant cells, which assist in biomaterial degradation or may indicate a foreign
body reaction [24–26]. Tissue integration is directly related to the inflammatory response and cell
invasion into the biomaterial [27]. A short inflammatory phase will ensure an early start of the
proliferative phase with mesenchymal cells invading the biomaterial [19]. Proliferation of cells into
the biomaterial is crucial for the integration of the biomaterial in the host tissue, denoting a high
biocompatibility [28,29]. Furthermore, the rigidity of a biomaterial determines cell invasion and the
cell type into which mesenchymal cells will differentiate [30]. Cell invasion into collagen scaffolds
depends on the presence of highly interconnected pores [31,32]. Furthermore, cell proliferation during
the early phase is dependent on the presence of vascular structures [28]. Endothelial and fibroblastic
cells work together, eventually leading to filling the voids of the biomaterial with collagen as part of
the extracellular matrix [19].
A first idea about the tissue response and the behavior of the VCMX after implantation was
obtained in a recently published, merely descriptive, study [19]. Currently, however, there are
no data available on the characterization of cells invading the VCMX and the dynamic changes
over time. Therefore, the aim of the present preclinical study is to qualitatively and quantitatively
evaluate the inflammatory response and invasion of blood vessels and proliferating cells into this
collagenous biomaterial. To this end, the VCMX was implanted in a clinically relevant canine model and
immunohistochemistry was used to characterize monocytes/macrophages (MAC387), multinucleated
giant cells (CD86), proliferating cells (PCNA), and blood vessels (TGII) invading the VCMX for an
observation period of 2 hours to 90 days.
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2. Materials and Methods
This preclinical study protocol has been approved by the Ethical Committee of NAMSA (ID number:
0041573) and conducted in accordance with the policies and principles of the Organization for
Economic Cooperation and Development Good Laboratory Practice regulations and the European
Union Guidelines (86/609/EEC).
2.1. Surgical Phase
Detailed protocol of animal selection and surgical phase can be found in a recent publication
using the same samples [19]. Briefly, six mature dogs weighing between 11.6 and 14.5 kg were selected
for the study. Six maxillary premolars were atraumatically extracted to create two edentulous spaces in
each dog. After 90 days, a full thickness flap was elevated, and either a VCMX (Fibro-Gide® prototype,
Geistlich Pharma AG, Wolhusen, Switzerland), in contact with the bone, was placed, or the flap was
repositioned without the use of a biomaterial (sham group). Wounds were closed by primary intention.
Sacrifice of animals was performed at days 0, 4, 7, 15, 30, and 90.
2.2. Scanning Electron Microscopy
The VCMX was gold-coated and observed at high-vacuum in a Zeiss 940 DSM Scanning Electron
Microscope (Carl Zeiss, Oberkochen, Germany).
2.3. Histologic Processing and Descriptive Analysis
Upon receiving the samples, tissue blocks were trimmed and left in 4% formalin for a period of
10 days. Demineralization was performed by leaving the tissue blocks in 10% ethylenediaminetetraacetic
acid (EDTA) for 5 weeks. Tissue blocks were divided into 3 sections and embedded in paraffin,
methylmethacrylate (MMA), or in acrylic resin (LR White, Sigma–Aldrich, St. Louis, MO, USA).
Paraffin sections were cut at 5 µm, while MMA-embedded tissues were cut with a diamond-coated
disc and ground to a thickness of 100 µm. LR White sections were cut at 1 µm with a diamond
knife on a Reichert Ultracut E microtome (Leica Microsystems, Wetzlar, Germany). MMA-embedded
sections were stained with basic fuchsin and toluidine blue, and LR White-embedded sections were
double stained with toluidine blue and basic fuchsin. Paraffin embedded sections were stained with
hematoxylin/eosin, Giemsa, or Masson’s trichrome. Digital photography was performed using a digital
camera (AxioCam MRc, Carl Zeiss, Oberkochen, Germany) connected to a microscope (Axio Imager
M2, Carl Zeiss, Oberkochen, Germany).
2.4. Preparation for MAC387 Immunohistochemistry
To visualize cells that belong to the inflammatory linage derived from hematopoietic stem
cells such as granulocytes, monocytes, and macrophages, the MAC387 antibody was used.
Tissue sections were deparaffinized and rehydrated, washed, and blocked 30 min with defatted milk.
Dako EnVisionTM + Dual Link System-HRP (DAB+) (Agilent, Santa Clara, (CA), USA) was used, adding
an incubation with Dako Proteinase K during 5 min. The MAC387 antibody (Anti-S100A9+Calprotectin,
Abcam, Cambridge, UK) was diluted 1:2000 and used overnight at 4 ◦C. Counterstaining of the samples
was performed with Mayer’s hematoxylin solution (Merck, Darmstadt, Germany).
2.5. Preparation for PCNA Immunohistochemistry
To visualize cells that were in a proliferative phase, paraffin-embedded sections underwent
inmunohistochemical staining with anti-proliferating cell nuclear antigen (PCNA, clone PC10) antibody
(DAKO, Glostrup, Denmark). Tissue sections were deparaffinized and rehydrated. Heat-induced
epitope retrieval was performed at 85 ◦C for 10 min with a citrate solution. Samples were blocked 30 min
with defatted milk, and Dako EnVisionTM + Dual Link System-HRP (DAB+) was used. Incubation
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with the antibody, diluted 1:50, was performed at room temperature for 1 h. Counterstaining of the
samples was performed with Mayer’s hematoxylin solution (Merck, Darmstadt, Germany).
2.6. Histologic Quantitative Analysis
Quantitative analysis was performed for cells labeled for PCNA and MAC387. Three pictures
were taken randomly at the margin and the center of the VCMX through the different time points (4, 7,
15, 30, 90 days). An area of 0.36 mm2 was delimited in every picture and positive cells were counted.
The paired t-test was used, and the statistical significance was established at p < 0.05.
2.7. Preparation for CD86 Immunohistochemistry
Paraffin-embedded sections underwent inmunohistochemical staining with an anti-CD86 antibody
(clone EP1158Y, CD86, Abcam). Heat-induced epitope retrieval was performed at 85 ◦C for 10 min with
a citrate solution. Samples were blocked 30 min with defatted milk, and Dako EnVisionTM + Dual Link
System-HRP (DAB+) was used. Incubation with the antibody was performed at room temperature for
2 h. The antibody was diluted 1:100. Counterstaining of the samples was performed with Mayer’s
hematoxylin solution (Merck, Darmstadt, Germany).
2.8. Preparation for TGM2 Immunohistochemistry
To stain blood vessels, paraffin-embedded sections underwent inmunohistochemical staining
with anti-Trans Glutaminase II antibody (clone CUB7402, TGM2, Thermo Fisher Scientific, Waltham,
MA, USA). Deparaffinized sections were blocked utilizing 3% hydrogen peroxide, and heat-induced
epitope retrieval was performed at 92 ◦C for 12 min with a citrate solution. Incubation with the 1:100
diluted antibody was performed at room temperature for 1 h. Wash buffer and secondary antibody
were purchased from Zytomed Systems GmbH (Berlin, Germany). Counterstaining of the samples
was performed with Mayer’s hematoxylin solution (Merck, Darmstadt, Germany).
3. Results
No surgical or healing complications were recorded in any of the animals. All tissue samples could
be harvested successfully and were processed histologically. The paraffin histology showed the presence
of the VCMX close to the bone surface along the maxillary alveolar process at all healing periods
(Figure 1A). Because of progressing integration in host tissue, the distinction between biomaterial
and surrounding tissue was most readily possible for healing periods up to 30 days. The biomaterial
displayed a trabecular structure forming large honeycomb-like interconnected pores (Figure 1B,C)
and consisted of an amorphous, sheet-like matrix with embedded, rod-like structures (Figure 1B).
In the 90-day sample, residual VCMX was still visible and well-integrated in soft connective tissue.
For reasons of consistency and standardization, the following description of the inmunohistochemical
results will be confined to the region facing the bone surface (see right rectangle in Figure 1A).
The VCMX was clearly identifiable and demarcated from the surrounding tissues up to 30 days.
At 4 days (Figure 2A), the connective tissue surrounding the VCMX showed the typical feature of
granulation tissue, i.e., presence of a fibrin network, many erythrocytes, small blood vessels, and some
leukocytes. Initial invasion of blood vessels, leukocytes, and mesenchymal cells into the VCMX
pores was observed at 4 days and restricted to the border region only. At 7 days (Figure 2B), larger
blood vessels and many mesenchymal cells were seen surrounding and invading the collagen scaffold.
At 15 days (Figure 2C), still many blood vessels, few inflammatory cells, and many spindle-shaped
fibroblasts oriented parallel to newly formed collagen fibers were seen external to the biomaterial.
Some residual biomaterial became integrated in the surrounding soft connective tissue. At 30 days
(Figure 2D), the surrounding host collagen matrix appeared more mature and the epithelial layer was
closed and well-keratinized. At the border, the biomaterial was well-integrated in the surrounding
more mature soft connective tissue, and inflammatory cells were scarce. At 90 days (Figure 2E), residual
islands of biomaterial were dispersed and well-integrated in the surrounding host soft connective tissue.
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Figure 1. (A) Overview of a paraffin-embedded tissue section stained with Hematoxylin and Eosin 
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marks the VCMX center. (B) The resin section illustrates the VCMX pores filled with blood plasma 
and mainly erythrocytes at 4 h (= day 0) after implantation. (C) The scanning electron microscopic 
image illustrates the three-dimensional-structure and pores of the VCMX. 
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Figure 2. Paraffin-embedded tissue sections stained with Masson’s trichrome showing the VCMX at 
different time points and in two different regions (A–K). While white arrows point to blood vessels 
in the surrounding soft connective tissue, yellow arrows mark blood vessels in the pores of the VCMX. 
Blood vessels inside the VCMX become clearly visible from day 7 on at the periphery and from day 
30 on in the center. 
3.1. Masson’s Trichrome Stain 
Immediately after implantation, the pores of the VCMX were mainly filled with erythrocytes 
and blood plasma. At 4 days, a fibrin network and erythrocytes were present within most pores in 
the peripheral part of the VCMX, whereas small blood vessels and mesenchymal-like cells were seen 
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progressively invaded the VCMX and increased in size and number at the periphery, and the number 
of scattered invading mesenchymal-like cells increased as well (Figure 2B). At 15 days, the VCMX 
pores were completely invaded by small blood vessels, mesenchymal-like cells within the pores had 
increased in numbers, and an extracellular matrix began to fill the pores (Figure 2C). At 30 days, 
many blood vessels, predominantly mesenchymal cells now resembling slender fibroblasts, and an 
extracellular matrix filled the VCMX pores (Figure 2D). At 90 days, packages of residual VCMX were 
fully integrated in soft connective tissue and the number of blood vessels was reduced and confined 
to the soft connective tissue surrounding the residual VCMX packages (Figure 2E,K). Compared to 
the marginal VCMX, the central region showed a delay in coagulation, invasion of both blood vessels 
and mesenchymal-like cells, and formation of extracellular matrix within the VCMX pores (Figure 
2F–K). This extracellular matrix was fibrous and increasingly filled the pores of the VCMX starting 
from the periphery at 7 days and progressing towards the center of the VCMX. 
3.2. Immunohistochemistry with the Anti-MAC387 Antibody 
MAC387+ cells were seen in the soft connective tissue next to the VCMX and in the peripheral 
part of the VCMX at 4 (Figure 3A) and 7 (Figure 3B) days. In the peripheral part of the VCMX, the 
number of positive cells was highest at 4 days, whereas only a few labeled cells were present after 15 
days (Figure 3C). Virtually no labelled cells were seen at 0, 30, and 90 days (Figure 3D,E). In the center 
of the VCMX, MAC387+ cells appeared with a delay. Labeled cells were seen at 4 days (Figure 3F) 
and peaked at 7 days (Figure 3G), after which the number of labeled cells sharply declined (Figure 
3H,I,K). 
Figure 2. Paraffin-embedded tissue sections stained with Masson’s trichrome showing the VCMX at
different time points and in two different regions (A–I,K). While white arrows point to blood vessels in
the surrounding soft connective tissue, yellow arrows mark blood vessels in the pores of the VCMX.
Blood vessels inside the VCMX become clearly visible from day 7 on at the periphery and from day 30
on in the center.
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3.1. Masson’s Trichrome Stain
Immediately after implantation, the pores of the VCMX were mainly filled with erythrocytes and
blood plasma. At 4 days, a fibrin network and erythrocytes were present within most pores in the
peripheral part of the VCMX, whereas small blood vessels and mesenchymal-like cells were seen in
the soft connective tissue adjacent to and invading the VCMX (Figure 2A). At 7 days, blood vessels
progressively invaded the VCMX and increased in size and number at the periphery, and the number
of scattered invading mesenchymal-like cells increased as well (Figure 2B). At 15 days, the VCMX
pores were completely invaded by small blood vessels, mesenchymal-like cells within the pores had
increased in numbers, and an extracellular matrix began to fill the pores (Figure 2C). At 30 days,
many blood vessels, predominantly mesenchymal cells now resembling slender fibroblasts, and an
extracellular matrix filled the VCMX pores (Figure 2D). At 90 days, packages of residual VCMX were
fully integrated in soft connective tissue and the number of blood vessels was reduced and confined to
the soft connective tissue surrounding the residual VCMX packages (Figure 2E,K). Compared to the
marginal VCMX, the central region showed a delay in coagulation, invasion of both blood vessels and
mesenchymal-like cells, and formation of extracellular matrix within the VCMX pores (Figure 2F–I,K).
This extracellular matrix was fibrous and increasingly filled the pores of the VCMX starting from the
periphery at 7 days and progressing towards the center of the VCMX.
3.2. Immunohistochemistry with the Anti-MAC387 Antibody
MAC387+ cells were seen in the soft connective tissue next to the VCMX and in the peripheral part
of the VCMX at 4 (Figure 3A) and 7 (Figure 3B) days. In the peripheral part of the VCMX, the number
of positive cells was highest at 4 days, whereas only a few labeled cells were present after 15 days
(Figure 3C). Virtually no labelled cells were seen at 0, 30, and 90 days (Figure 3D,E). In the center of
the VCMX, MAC387+ cells appeared with a delay. Labeled cells were seen at 4 days (Figure 3F) and
peaked at 7 days (Figure 3G), after which the number of labeled cells sharply declined (Figure 3H,I,K).
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Figure 3. Inmunohistochemical staining with the anti-MAC387 antibody at different time points and in
peripheral and central regions of the VCMX. Brown (DAB+) cells indicate presence of macrophages.
Four days after implantation, MAC387+ cells are present in the soft connective tissue surrounding the
VCMX and in th VCMX pores (A,F). Most MAC387+ cells are seen in t peripheral part at 4 days (A)
and in the center at 7 days (G), while they decrease o the periphery (B . Thereafter, the number of
positive cells sharply decreased (C,H). No labelled cells can be seen after 30 (D,I) and 90 days (E,K)
of implantation.
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3.3. Immunohistochemistry with the Anti-PCNA Antibody
At 4 days, PCNA+ cells were seen in large numbers in the soft connective tissue next to the VCMX
and also in some cells invading the peripheral portion of the VCMX (Figure 4A). The number of
positive cells increased up to 15 days (Figure 4B,C) followed by a slow decline over time (Figure 4D,E).
Up to 7 days, there were very few PCNA+ cells in the center of the VCMX (Figure 4F,G). The highest
number of positive cells in the center was observed at 15 days (Figure 4H) followed by a slow decline
up to 90 days (Figure 4I,K).
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biomaterial. 
 
Figure 4. Inmunohistochemical staining for PCNA to detect proliferating cells at different time points in
peripheral and central regions of the VCMX. Brown (DAB+) nuclei indicate proliferating cells. PCNA+
cells are present in large numbers outside and inside (periphery) of the VCMX at day 4 (A), whereas the
VCMX center is devoid of labeled cells (F). While the number of PCNA+ cells increases in the periphery
up to 15 days (B,C), the first PCNA+ cells in the center appear on day 7 (G) and increase on day 15 (H).
The number of PCNA+ cells gradually decreased over time both in the periphery (D,E) and in the
center (I,K) of the VCMX.
3.4. Quantitative Histological Analysis for MAC387 and PCNA
The counts of cells positive for MAC387 and PCNA are illustrated in Figure 5A,B, respectively.
The number of MAC387+ cells reached its maximum at day 4 in the peripheral region of the biomaterial.
At day 7, the number of MAC387+ cells in the periphery of the biomaterial was reduced to 50%,
and at days 30 and 90 no MAC387+ cells could be detected anymore. In the central part of the VCMX,
MAC387+ cells peaked at day 7, after which a sharp decline was observed. The highest number of
MAC387+ cells was observed in the central part of the biomaterial.
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margins of the VCMX at day 4, while the peak at the center was at 7 days. PCNA+ cells peaked at day 
15 and reduced gradually over time. *P < 0.05, **P < 0.01. 
3.5. Immunohistochemistry with the Anti-CD86 Antibody 
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At 7 and 15 days, labeling of small blood vessels persisted and more scattered cells were labeled 
(Figure 6B,C). At 30 days, some blood vessels were still weakly positive, and the number of scattered 
positive cells had declined (Figure 6D). At 90 days, a few blood vessels and declined number of 
scattered cells were weakly positive (not shown). In the central region of the VCMX, no (Figure 6E) 
or very few (Figure 6F) faintly CD86+ scattered cells were seen at 4 and 7 days, respectively. Up to 7 
days (Figure 6F), no positive staining of blood vessels was observed in the central part of the VCMX. 
At 15 and 30 days, the blood vessels in the center of the VCMX were medium-sized, their endothelial 
cells were flat, and immunolabeling was present (Figure 6G,H). Only very few scattered cells showed 
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time within the central pores of the VCMX. Only at 7 and 15 days did a few multinucleated giant cells 
showed a very weak labeling for CD86 at the periphery of the VCMX. 
Figure 5. Bar charts showing the quantitative analysis (labeled cells/0.36 mm2) of (A) MAC387+ and
(B) PCNA+ cells throughout the different time points. Cells positive for MAC387 peaked at the margins
of the VCMX at day 4, while the peak at the center was at 7 days. PCNA+ cells peaked at day 15 and
reduced gradually over time. * p < 0.05, ** p < 0.01.
In the peripheral part of the biomaterial, the number of PCNA+ cells increased from 4 to 15 days,
followed by a decline. In the central part of the bi material, the first PCNA+ cells were detected at day
7, reached a maximum at 15 days, and declined thereafter. In the peripheral and central part of the
biomaterial, the numbers of proliferative cells decreased from 15 days to 30 days by 25%, indicating
that the proliferative phase was slowing down. After 90 days, the number of PCNA+ cells dropped by
75%. The highest number of PCNA+ cells was observed in the central part of the biomaterial.
3.5. Immunohistochemistry with the Anti-CD86 Antibody
In the marginal region, very weak labeling for CD86 was observed at 4 days in association with
small blood vessels with thickened endothelial cells and in a few single scattered cells (Figure 6A).
At 7 and 15 days, labeling of small blood vessels persisted and more scattered cells were labeled
(Figure 6B,C). At 30 days, some blood vessels were still weakly positive, and the number of scattered
positive cells had declined (Figure 6D). At 90 days, a few blood vessels and declined number of
scattered cells were weakly positive (not shown). In the central region of the VCMX, no (Figure 6E) or
very few (Figure 6F) faintly CD86+ scattered cells were seen at 4 and 7 days, respectively. Up to 7 days
(Figure 6F), no positive staining of blood vessels was observed in the central part of the VCMX. At
15 and 30 days, the blood vessels in the center of the VCMX were medium-sized, their endothelial
cells were flat, and immunolabeling was present (Figure 6G,H). Only very few scattered cells showed
positive labeling (Figure 6G,H). Large multinucleated CD86+ cells were not observed at any healing
time within the central pores of the VCMX. Only at 7 and 15 days did a few multinucleated giant cells
showed a very weak labeling for CD86 at the periphery of the VCMX.
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Figure 6. Inmunohistochemical staining for CD86 at different time points in peripheral and central
regions of the VCMX. Brown (DAB+) staining indicates CD86+ macrophages and endothelial cells.
At day 4, a few single scattered cells and blood vessels in the peripheral pores of the VCMX are labeled
for CD86 (A), whereas the center does not show any labeled cells (E). At days 7 and 15, the number of
CD86+ scattered cells and endothelial cells had increased at the periphery (B,C). In the central pores
the first CD86+ cells appeared after 7 days (F) and increased at 15 days (G). After 30 days, the number
of CD86+ scattered cells had decreased but blood vessels were still positive (D,H).
3.6. Immun histochemistry with the Anti-TGM2 Antibody
Numerous small blood vessels w re seen in the soft conn ctive tissue adjacent to the VCMX and
started to invade the VCMX pores from day 4 onwards and reached the central a s. Thus,
blood vessel invasion was delayed in more central regions. Figure 7 shows immunostaining of blood
vess l (asterisks) at day 7 at the peri hery of the biomateri l (Figure 7A) but no positive reaction in
the ce tral r gion (Figure 7C). After 90 days, TGM2+ blood vessels were pr s nt in the soft connective
tissue surrounding the residual VCMX matrix packages (Fi ure 7B,D).
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4. Discussion
The soft tissue plays an important role in the maintenance of health around teeth and dental
implants. Lack of an adequate volume of soft tissue can be corrected using autogenous soft tissue
grafts or biomaterials. The advantage of using biomaterials is that no second surgical intervention is
needed and that they are available at high quantities. The most widely used biomaterial for soft tissue
augmentation is collagen-based, since it is believed that such a material mimics best the natural cell
environment of the extracellular matrix [33], although other biomaterials are also candidates for soft
tissue regeneration [28,34]. Collagenous matrices vary with respect to composition, three-dimensional
structure, elasticity, and mechanical stability. If a collagen matrix collapses after implantation, host cell
migration and blood vessel penetration may be impaired, which in turn negatively influences tissue
degradation and integration as well as extracellular matrix production in the interior of the biomaterial.
Thus, volume stability is an important parameter of biomaterials used for tissue augmentation.
A second important factor is the inflammatory response to the implanted biomaterial. In the present
study, we investigated the inflammatory response and cell migration into a novel volume-stable
collagen matrix (VCMX), developed with the purpose of increasing the width of soft connective tissue.
The VCMX tested was described in three studies in canines where the focus was on volume gain
and volume changes over time [21,35,36]. These studies have shown that gain of thickness of newly
formed tissues adjacent to bone and dental implants was observed up to three months, but not so in the
long-term, i.e., at six months. The authors concluded that the applied histomorphometrical techniques
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might not have been ideal to assess linear and volumetric tissue changes. However, the descriptive
histology demonstrated favorable tissue integration in all three studies, but in none of the studies
were the early healing events and the sequence of healing evaluated. As shown in the present study,
the VCMX tested consists of an amorphous sheet-like matrix and small fibers and formed a trabecular
structure containing large honeycomb-like pores. A recent study concluded that the sheet-like matrix
was collagen and the small fibers were elastin [19]. In the present study, the histology showed that the
VCMX did take up blood after its implantation but did not collapse (see Figure 1A,B). Other biomaterials
used for soft tissue augmentation may collapse when they come in contact with liquids like blood.
Recent studies have shown that invasion of host cells into a biomaterial is dependent on a pathway of
interconnected pores [31,32]. Thus, interconnectivity of pores in the biomaterial scaffold and resistance
to collapse are important requirements for tissue integration and regeneration.
The inflammatory and immune response determines the fate of a biomaterial and the type of tissue
formed. In the worst case, a foreign body reaction may develop [33,37]. In the best scenario, wound
healing is uneventful, displaying a short transient inflammatory phase after which the biomaterial
becomes fully integrated in the host tissue. In this regard, cells from the monocyte/macrophage lineage
play a pivotal role. Macrophages are among the cells that first come in contact with an implanted
biomaterial. Macrophages possess a high plasticity; they are capable of polarizing from contributors
of tissue inflammation (pro-inflammatory M1 macrophage) towards contributors of wound healing
and tissue regeneration (anti-inflammatory M2 macrophage) [38]. M1 macrophages are an absolute
requirement in the early wound healing phase. However, if the M1 macrophage phenotype persists
and no shift to M2 macrophages occurs, an extended inflammatory phase ensues, eventually leading
to the formation of multinucleated giant cells. Indeed, the prolonged presence of inflammatory cells is
related to a foreign body reaction to the implanted biomaterial, especially during the first two to four
weeks after implantation [39]. The present study has shown that MAC387+ (for macrophages) and
CD86+ (for both multinucleated giant cells and M1 macrophages) [24] cells are only present for a short
period of time. Furthermore, the few CD86+ multinucleated giant cells were only detected at days
7 and 15 and were exclusively at the peripheral interface between the biomaterial and surrounding
soft connective tissue. These cells may have a function in the degradation of the biomaterial. CD86 is
traditionally used as an M1 macrophage marker, but it is reported that endothelial cells can also express
CD86 [40]. In the present study, CD86+ newly formed blood vessels were present at the marginal
portion of the biomaterial and approaching the biomaterial center in less than a week.
Apart from being key players during the inflammatory phase, macrophages have an influence on
angiogenesis [41,42] and fibroblast proliferation and activity [43]. In the present study, the first blood
vessels invading the biomaterial were seen after 4 days and reached the center at day 15. Another factor
contributing to invasion and proliferation of cells is biomaterial micro-architecture and composition [44].
For example, a biomaterial with interconnected pores supports invasion and ingrowth of cells [45].
This not only helps ingrowth of new cells but also facilitates nutrient and oxygen diffusion [45].
In addition, a certain pore size and interconnectivity of pores facilitate angiogenesis [46]. The favorable
three-dimensional structure of the VMCX may have contributed to the observed fast ingrowth of
blood vessels. Whether or not macrophages contributed to angiogenesis in our experimental setting
requires further studies. However, what is known is that anti-inflammatory M2 macrophages, rather
than pro-inflammatory M1 macrophages, promote angiogenesis [41]. Unfortunately, we could not find
antibodies against M1 and M2 macrophages that worked in canine tissues. We tested about six other
anti-macrophage antibodies without having success, and the anti-MAC387 antibody was the only
anti-macrophages antibody that was working in canine tissues. Regarding cell proliferation, we have
shown that the pores of the VCMX were not only rapidly invaded by blood vessels but also by other
fast proliferating cells. The proliferative PCNA+ cells started to invade the VCMX after 4 days and
reached the center after 7 days. The peak of the proliferative phase was at day 15 with a short delay in
the central part of the biomaterial. Since no inflammatory cells were detected after 15 days, it seems
likely that these cells were mesenchymal cells, probably fibroblasts. The morphology of these cells
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supports this assumption. Fast ingrowth of blood vessels coupled with fast proliferating cells such as
fibroblasts, which eventually will start to produce collagen as part of the newly formed extracellular
matrix, ensures rapid integration of the biomaterial into the host tissue. This, in turn, may assist in
maintaining the volume of the implanted biomaterial, as part of it may undergo degradation over time.
The present study provides sound biological knowledge about the tissue response towards a
new biomaterial for soft tissue augmentation. Nevertheless, the study has limitations. One of the
limitations of the present study is the small sample size. We therefore consider this experiment as a
pilot study to explore the possibilities using immunohistochemical techniques to evaluate the tissue
response towards a biomaterial in the canine, an animal very rarely used for biomaterial testing. In this
sense, the study is unique and provides very valuable data for future studies in the biomaterial field.
The results are very coherent, showing a logical sequence of events with a short inflammatory phase
and a rapid ingrowth of non-inflammatory cells. Further studies may use a higher number of samples
and may also address the tissue response and integration of this biomaterial in humans.
5. Conclusions
The VCMX appeared volume-stable and elicited a short inflammatory phase and fast ingrowth
of blood vessels and non-inflammatory cells resulting in a complete integration in the host tissue.
Overall, the present study demonstrates a high biocompatibility of the VCMX, which makes it a potent
candidate for soft connective tissue augmentation in dentistry and possibly also other disciplines.
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